

A 6-month Ibudilast Treatment Regimen Aimed to Improve Brain Function in Patients with Myalgic Encephalomyelitis/Chronic Fatigue syndrome: A Case Study.

Christof Peter Zizaja^{1,2,3} PhD1 Susanne Young^{3,4} PhD2; Jan Sedlaczek⁵; Thomas Lindner²; Michael Sadra Chirazi-Stark³.
 1 Akademia Wychowania Fizycznego im. Politechniki Wrocławskiej, University of Wrocław, Al. Paderewskiego 35, PL 51-617 Wrocław, Poland. 2 UK Department of Neuroradiology Hamburg, Martinistraße 52, WEST 14, Room 57, 20251 Hamburg. 3 Institut of Stress Diagnostic and Intervention Fatigue Science, Prof Stark, Beim Schlump 29, 20144 Hamburg. Email kontakt@prof-stark.de. 4 South African PTSD Research Program of Excellence, Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University. Email . 5 Biomedical Engineering Department and Centre for the Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London UK.

ABSTRACT

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) represents a complex condition whose onset is potentially linked to viral infections or immune-mediated disturbances, instigating inflammatory processes with repercussions on brain interconnectivity. Ibudilast, originally developed for Amyotrophic Lateral Sclerosis (ALS), demonstrates the potential to stimulate myelin growth.

This case study explores the intricate relationship between viral infections and vector markers within diverse brain networks, employing Fractional Anisotropy (FA) imaging as a primary investigative tool. A comprehensive analysis of 120 brain volumes is conducted, tracking changes over time and capturing unique characteristics. Automated fibre quantification facilitates the comparison of FA along 12 specific tracts.

The study encompasses two ME/CFS patients subjected to a six-month ibudilast regimen, alongside two untreated ME/CFS patients. Diagnoses are meticulously established through clinical evaluation, self-reported assessments, alignment with the Canadian Consensus Criteria for CFS, and ICD-10 coding.

These findings illuminate the potential implications of Ibudilast in managing ME/CFS and underscore the imperative need for further research into this complex syndrome.

METHODS

- We examined 12 primary fibre tracts from a total of 42 available in the Diffusion MRI Atlas.
- The tract atlas, obtained from the Center for Biomedical Imaging at Massachusetts General Hospital and Harvard Medical School, was manually annotated.
- TRACULA software was employed to reconstruct the tracts based on the atlas.
- DTI, a variant of magnetic resonance imaging, was used to measure water molecule movement in the brain, allowing visualization of nerve fibres in white matter.
- Data processing involved importing DCM files into Horos and converting them for analysis with TRACULA and FreeSurfer.
- Fractional Anisotropy (FA) measured the diffusion of water molecules in the tissue, indicating anisotropy.
- Additionally, Radial Diffusivity (RD), representing myelin sheath inflammation, and Axial Diffusivity (AD), reflecting axonal damage, were analysed.
- Brain regions including the hypothalamus, lateral ventricles, cerebellum white matter volume, cerebellum cortex, hippocampus, amygdala, thalamus, and fornix were examined.
- Ibudilast was initially administered at 10mg/day and increased to 30mg/day after 3 months due to its phosphodiesterase inhibition and anti-inflammatory effects.

RESULTS

- Unexpectedly, ME/CFS patients showed a deterioration over a 3-year period, suggesting a progressive decline in neuronal processes.
- Comparing baseline measurements, a 10-30% decrease in axial diffusivity was observed in 12 brain regions.
- Ibudilast treatment led to improved brain coherence and reduced high fibre activity in axial diffusivity in 8 brain network areas.
- Treatment-naïve patients exhibited a 10-20% increase in axial diffusivity in the right cerebellum.
- Heart rate variability and hypothalamus volume normalized within the treatment group.
- No significant volume changes were noted in the test group.
- In ME/CFS individuals, increased right anterior arcuate and highly elevated inferior longitudinal fasciculus (ILF) fibre crossings were observed when considering insular cortex fibres.
- Axial diffusivity changes in the right cerebellum were detected in both ME/CFS and LC patients, possibly impacting body awareness and peripheral neuromuscular impulse feedback.
- These findings could provide insights into the persistent symptoms of LC and ME/CFS, but further patient data is needed for validation.

RESULTS




Fig. 2 The right Hippocampus of the Control Group is represented in olive color, highlighting its significant volumetric reduction from 2021 to 2023. The reduction is indicated by the red arrow.




Fig. 1 depicts volumetric changes across 12 distinct areas, organized into twelve groups. In Group 1, the two front bars highlighted in light blue represent the Control Group, while the dark blue bars within Section 1 pertain to the Intervention Group following ibudilast application. Notably, substantial volumetric changes were observed, especially within the Control Group, where increases in volume were prominent in the left Amygdala, right Cerebellum Cortex, and right Lateral Ventricle areas.




Fig. 5 Shows the 12 Fibre Sections examination of the fractional anisotropy.

CONCLUSIONS

- The results obtained in this study raise the possibility that Ibudilast could be a viable option for enhancing brain function among individuals with ME/CFS. Furthermore, these findings present fractional anisotropy as a potential biomarker that holds promise for diagnosing both ME/CFS and LC, offering a valuable tool for identifying and distinguishing these conditions.

ACKNOWLEDGEMENTS

- We would like to thank the patients at Prof Stark Institut, and the healthy volunteer, for their participation and making available of their patient data for the advancement of our knowledge of CNS dysregulation in ME/CFS and PCS

REFERENCES

Baranik James N. et al.: Differential Effects of Exercise on fMRI of the Midbrain Ascending Arousal Network Nuclei in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Gulf War Illness (GWI) in a Model of Postviral Malaise (PEMA). In: *Brain Sci.* 12, 78 <https://doi.org/10.3390/brainsci12010078>, 2022

Barnea-Goraly, N. et al.: White Matter Development During Childhood and Adolescence: A Cross-Sectional Diffusion Tensor Imaging Study. In: *Cerebral Cortex* 15, S. 1848-1854, 2005

Basser, P. et al.: MR Diffusion Tensor Spectroscopy and Imaging. In: *Biophysical Journal* 66, S. 259-267, 1994

Billet B. et al.: Automated segmentation of the hypothalamus and associated subunits in brain MRI, in Print, 2023

Byrne H. et al.: Hypothalamus volumes in adolescent Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): impact of self-reported fatigue and illness duration. In: *Brain Structure and Function*, May 2023

Hewig S. J. et al.: On the selective relation of frontal cortical asymmetry and anger-out versus anger-control. *Journal of Personality and Social Psychology*, 87(6), Page 926-939, 2004

Maffei C. et al.: Using diffusion MRI data acquired with ultra-high gradients to improve tractography in routine-quality data. In: *Neuroimage* 245:118706, 2021

Zeineh M.M. et al.: Right Arcuate Fasciculus abnormality in chronic fatigue syndrome. *Radiology*, Volume 274, Number 2 February 2015

Zizaja P.C. et al.: Autonomic Nervous System Functioning in Patients with Post Viral Syndrome: A Case-Series Study of a Healthy Control Subject, a Long Covid patient and a ME-CFS patient. In 2022 Clinical and Scientific Conference Stony Brook University, NY, USA

Zizaja CP, Young S, Sedlaczek J, Lindner T, et al. (2023) Comparing Fractional Anisotropy Diffusion Tensor Imaging of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Long COVID and Healthy Controls. 2nd International Meeting of the CFS – Charité Fatigue Center Berlin 11 May – 12 May at the Universitätsmedizin 2023 Berlin